New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
February 11, 2008 — Investigators have found that insulin-like growth factor binding protein 7 (IGFBP7), a secreted protein, dramatically influences the ability of an activating BRAF mutation to ...
CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...
Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas. A new review article offers insights into patients with ...
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...
This article is based on a poster originally authored by Qiuyuan Yang, Kaiqiang Hu, Lei Liu, Tingting Guo, Haiyan Gu, Pengwei Pan, and Fang He. The study aimed to unravel the underlying processes that ...
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results